Candida testing market seen reaching $22.56 billion by 2030

The candida infection testing market is projected to grow from $17.8 billion in 2026 to $22.56 billion by 2030, driven by rising fungal infections, more immunocompromised patients and wider use of rapid diagnostics. North America held the largest share in 2025, while molecular testing and point-of-care tools are expected to expand the market further.

Why it matters: - Candida infection testing helps doctors identify fungal infections early and choose the right treatment. - Demand for testing is rising as yeast infections and antifungal resistance become more common. - Faster and more precise diagnostics can improve care for immunocompromised patients and reduce delays in treatment.

What happened: - The candida infection testing market is projected to rise from $17.8 billion in 2026 to $22.56 billion by 2030. - The forecast implies a 6.1% compound annual growth rate through 2030. - The market was valued at $16.72 billion in 2025 and is estimated to reach $17.8 billion in 2026, a 6.4% CAGR in that period. - The Business Research Company released the market outlook on Nov. 6, 2026.

The details: - Growth has been supported by more fungal infection cases, more immunocompromised patients and wider hospital diagnostic availability. - Culture-based fungal testing remains part of the market's current base. - Future growth is expected to come from rapid fungal diagnostics, molecular testing, microbiome testing and point-of-care fungal diagnostic options. - Investment in infectious disease diagnostics and personalized antifungal treatments is also expected to support demand. - Notable trends include broader use of molecular detection methods, rapid nucleic acid amplification test-based diagnostics, microbiome assessments and hospital-based fungal testing. - Candida infection testing includes diagnostic methods used to detect candida species and assess the type and severity of infection. - The tests help clinicians tailor treatment plans. - The market report is available as a free sample. - The full report is also available.

Between the lines: - Rising bloodstream yeast infections add urgency to the testing market. - UK Health Security Agency data showed bloodstream yeast infections in England rose 4% in 2024 from 2,170 cases to 2,247 cases, with incidence increasing from 3.8 to 3.9 per 100,000 people. - North America held the largest share of the global market in 2025. - Other regions tracked in the report include Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Emerging markets outside North America are expected to grow as healthcare infrastructure expands and disease awareness increases.

What's next: - The market is expected to keep expanding as rapid diagnostics and molecular tools gain wider adoption. - Hospital-based testing and early infection detection are likely to remain key growth areas. - The report points to more use of data tools, including TAM analysis, company scoring matrices and forecasting dashboards, in future editions. - The Business Research Company provided media contacts for further information and expert discussion.

The bottom line: - Candida infection testing is moving from a niche diagnostic segment to a broader growth market, with faster tests and higher infection rates driving the next phase of expansion.